Aurobindo Pharma is currently the top gainer on the BSE, with the stock price surging over 5% at Rs.809.50 and it presently remains around the same levels.

This sudden spike of interest in the stock price is on account of it getting a lot of “buy” calls from several brokerage houses. Credit Suisse in fact has put out a report stating that it has started coverage on the stock, giving it an “outperform” rating and putting a target price of Rs.950, which is some 17-18% higher than the current market price.

This report from Credit Suisse follows yesterday’s report by Goldman Sachs which also stated it too was covering the stock. Other initiating a buy call are ICICIDirect with a target price of Rs.990, Religare giving a target price of Rs.935, Emkay giving a target price of Rs.905, Prabhudas Lilladher’s target is  t Rs.943.